Detecting Tumor Immune Rejection with MRI
Author Information
Author(s): Hu D-E, Beauregard D A, Bearchell M C, Thomsen L L, Brindle K M
Primary Institution: Department of Biochemistry, University of Cambridge
Hypothesis
Can dynamic contrast agent-enhanced MRI (DCE-MRI) detect changes in tumor vascularity during immune rejection before any reduction in tumor volume occurs?
Conclusion
DCE-MRI can be used to detect early signs of tumor immune rejection by monitoring changes in vascularity.
Supporting Evidence
- DCE-MRI measurements showed increased vascularity in regressing E.G7-OVA tumors compared to non-regressing tumors.
- Significant infiltration of CD8+ T cells was observed in regressing tumors.
- Vascular endothelial growth factor (VEGF) levels were significantly higher in regressing tumors.
Takeaway
Doctors can use special MRI scans to see if a tumor is responding to treatment even before it gets smaller.
Methodology
The study used dynamic contrast agent-enhanced MRI to measure tumor perfusion and vascular changes in a mouse model of tumor immunotherapy.
Limitations
The study was conducted in a mouse model, which may not fully represent human tumors.
Participant Demographics
Female C57BL/6 mice, aged 6-8 weeks.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website